Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice

Menopause

Volumn 15, Issue 1, 2008, Pages 98-104

  Abu Fanne, Rami ^a   Brzezinski, Amnon ^a   Golomb, Mordechai ^a   Grad, Etty ^a   Foldes, A Joseph ^a   Shufaro, Yoel ^a   Varon, David ^a   Brill, Alexander ^a   Lotan, Chaim ^a   Danenberg, Haim D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Estrogen; Raloxifene; Selective estrogen receptor modulator; Thrombosis; Vascular injury

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; PLACEBO; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BLOOD VESSEL OCCLUSION; BONE DENSITY; BONE MASS; CAROTID ARTERY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; LUNG PARENCHYMA; MENOPAUSAL SYNDROME; NONHUMAN; OVARIECTOMY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; UTERUS;

ANIMALS; ARTERIES; BONE DENSITY; ESTRADIOL; FEMALE; HOMEOSTASIS; MENOPAUSE; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PLATELET ADHESIVENESS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 38049088116     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318054e2ab     Document Type: Article

References (38)

1. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
2. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1:1371-1380.
3. Brzezinski A, Danenberg HD. Estrogen, progesterone, and cardiovascular health: when shall we complete the puzzle? Menopause 2005;12:488-491.
4. Geraldes P, Sirois MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2002;22:1585-1590.
5. Iwakura A, Luedemann C, Shastry S, et al. Estrogen mediated, endothelial nitric oxide synthase dependent mobilization of bone-marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003;108:3115-3121.
6. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.
7. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998;280:605-613.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
9. Baumer AT, Wassmann S, Ahlbory K, et al. Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene. Br J Pharmacol 2001;134:579-584.
10. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-1101.
11. Tsang SY, Yao X, Essin K, et al. Raloxifene relaxes at cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca channels. Stroke 2004;35:1709-1714.
12. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelial-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003;42:698-704.
13. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001;103:1497-1502.
14. Oviedo PJ, Hermenegildo C, Cano A. Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2. Menopause 2004;11:430-437.
15. Blum A, Cannon RO III. Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men. Ann N Y Acad Sci 2001;949:168-174.
16. Richardson MA, Berg DT, Calnek DS, Ciaccia AV, Joyce DE, Grinnell BW. 17β-Estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway. Endocrinology 2000;141:3908-3911.
17. Gordon MN, Osterburg HH, May PC, Finch CE. Effective oral administration of 17β-estradiol to female C57BL/6J mice through the drinking water. Biol Reprod 1986;35:1088-1095.
18. Nagashima M, Yin ZF, Zhao L, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002;109:101-110.
19. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003;108:512-515.
20. Varon D, Dardik R, Shenkman B, et al. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997;85:283-294.
21. Varon D, Lashevski I, Brenner B, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:S187-S193.
22. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-344.
23. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
24. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
25. Vitale C, Cornoldi A, Gebara O, et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause 2005;12:552-558.
26. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
27. Grosser T, Zucker TP, Weber AA, et al. Thromboxane A2 induces cell signaling but requires platelet-derived growth factor to act as a mitogen. Eur J Pharmacol 1997;319:327-332.
28. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004;114:784-794.
29. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306:1954-1957.
30. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000;343:1520-1528.
31. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
32. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
33. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
34. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-1492.
35. Okano H, Jayachandran M, Yoshikawa A, Miller VM. Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. J Cardiovasc Pharmacol 2006;47:621-628.
36. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-2969.
37. Hisamoto K, Ohmichi M, Kanda Y, et al. Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 2001;276:47642-47649.
38. Wong CM, Yao X, Au CL, et al. Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. Vasc Pharmacol 2006;44:290-298.